2025
Patidar, K., Ma, A., Juanola, A., et al.: Global epidemiology of acute kidney injury in hospitalized patients with cirrhosis: the International Club of Ascites GLOBAL AKI Prospective Cohort Study.
Lancet Gastroenterol. Hepatol. "Accepted by Publisher"2025.
Snijders, R., Janik, M., Mund, M., et al.: Health-related quality of life is impaired in people with autoimmune hepatitis: results of a multicentre cross sectional study within the European Reference Network.
Hepatology. "Accepted by Publisher"2025.
2024
Guba, A., Kováts, P., Mezei, Z., Papp, M., et al.: Analysis of Azathioprine Metabolites in Autoimmune Hepatitis Patient Blood-Method Development and Validation.
Int. J. Mol. Sci. 25 (20), 1-12, 2024.
Stern, L., Schmidt, C., Kocheise, L., et al.: Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma.
Ann. Hepatol. 29 (6), 1-6, 2024.
Weltzsch, J., Bartel, C., Waldmann, M., et al.: Optimizing thiopurine therapy in autoimmune hepatitis: a multi-center study on monitoring metabolite profiles and co-therapy with allopurinol.
Hepatology. 80 (5), 1026-1040, 2024.
Torp, N., Israelsen, M., Coenraad, M., Papp, M., et al.: Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a study protocol of a randomised clinical biomarker validation trial.
BMJ Open. 14 (2), 1-8, 2024.
Schregel, I., Papp, M., Sipeki, N., et al.: Unmet needs in autoimmune hepatitis: results of the prospective multicentre European Reference Network Registry (R-LIVER).
Liver Int. 44 (10), 2687-2699, 2024.
2023
Tornai, D., Mitchell, M., McClain, C., et al.: A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: a multicenter plasma biomarker analysis.
Hepatol. Commun. 7 (12), 1-13, 2023.
Uhlenbusch, N., Bal, A., Balogh, B., et al.: Improving quality of life in patients with rare autoimmune liver diseases by structured peer-delivered support (Q.RARE.LI): study protocol for a transnational effectiveness-implementation hybrid trial.
BMC Psychiatry. 23 (1), 1-11, 2023.
Váncsa, S., Sipos, Z., Váradi, A., et al.: Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course: Post hoc analysis of a prospectively collected international registry.
United European Gastroenterol J. 11 (4), 371-382, 2023.
Cho, Y., Bukong, T., Tornai, D., et al.: Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcoholic hepatitis.
J. Hepatol. 78 (1), 28-44, 2023.
Walmsley, M., Tornai, D., Cazzagon, N., et al.: Patient-reported quality of care in primary sclerosing cholangitis.
Liver Int. 43 (8), 1654-1662, 2023.
Weiss, E., de la Pena, -., Aguilar, F., et al.: Sympathetic nervous activation, mitochondrial dysfunction, and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
Gut. 72 (8), 1581-1591, 2023.
Janka, T., Tornai, D., Papp, M., Vitális, Z.: The Value of Neutrophil-to-Lymphocyte Ratio to Identify Bacterial Infection and Predict Short-Term Mortality in Patients with Acutely Decompensated Cirrhosis.
Diagnostics. 13 (18), 1-14, 2023.
2022
Tornai, D., Vén, P., Lakatos, P., Papp, M.: Serological biomarkers for management of primary sclerosing cholangitis.
World J. Gastroenterol. 28 (21), 2291-2301, 2022.
2021
Tornai, D., Antal-Szalmás, P., Tornai, T., et al.: Abnormal ferritin levels predict development of poor outcomes in cirrhotic outpatients: a cohort study.
BMC Gastroenterol. 21 (1), 1-13, 2021.
Moreau, R., Gao, B., Papp, M., et al.: Acute-on-Chronic Liver Failure: a distinct clinical syndrome.
J. Hepatol. 75 (Suppl1), S27-S35, 2021.
Tornai, D., Papp, M.: Editorial: serologic antibodies in primary sclerosing cholangitis - a tell-tale sign of compromised gut-liver immunity?.
Aliment. Pharmacol. Ther. 53 (2), 350-351, 2021.
Tornai, D., Vitális, Z., Jónás, A., et al., Antal-Szalmás, P.: Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality.
Clin. Res. Hepatol. Gastroenterol. 45 (5), 1-12, 2021.
Trebica, J., Fernández, J., Papp, M., et al.: PREDICT identifies Precipitating Events Associated with Clinical Course of Acutely Decompensated Cirrhosis.
J. Hepatol. 74 (5), 1097-1108, 2021.
2020
Tornai, D., Szabó, G.: Emerging medical therapies for severe alcoholic hepatitis.
Clin Mol Hepatol. 26 (4), 686-696, 2020.
Janka, T., Tornai, T., Borbély, B., Tornai, D., et al: Deleterious effect of proton pump inhibitors on the disease course of cirrhosis.
Eur. J. Gastroenterol. Hepatol. 32 (2), 257-264, 2020.
Gatselis, N., Tornai, T., Shums, Z., et al: Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients.
World J. Gastroenterol. 26 (34), 5130-5145, 2020.
Pape, S., Gevers, T., Vrolijk, J., et al.: High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation.
Liver Int. 40 (9), 2164-2171, 2020.
Pape, S., Gevers, T., Maarten Vrolijk, J., et al.: Rapid Response to Treatment of Autoimmune Hepatitis Associated with Remission at 6 and 12 Months.
Clin. Gastroenterol. Hepatol. 18 (7), 1609-1617, 2020.
Lowe, P., Cho, Y., Tornai, D., et al.: Inhibition of the Inflammasome Signaling Cascade Reduces Alcohol Consumption in Female But Not Male Mice.
Alcohol. Clin. Exp. Res. 44 (2), 567-578, 2020.
Trebica, J., Fernández, J., Papp, M., et al.: The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.
J. Hepatol. 73 842-854, 2020.
2019
Fernández, J., Prado, V., Trebica, J., et al.: Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with ACLF across Europe.
J. Hepatol. 70 (3), 398-411, 2019.
Saha, B., Tornai, D., Kodys, K., Adejumo, A., Lowe, P., McClain, C., Mitchell, M., McCullough, A., Dasarathy, S., Kroll-Desrosiers, A., Barton, B., Radaeva, S., Szabó, G.: Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.
Hepatology. 70 (4), 1134-1149, 2019.
Tornai, D., Furi, I., Shen, Z., Sigalov, A., Coban, S., Szabó, G.: Inhibition of Triggering Receptor Expressed on Myeloid Cells 1 Ameliorates Inflammation and Macrophage and Neutrophil Activation in Alcoholic Liver Disease in Mice.
Hepatol. Commun. 3 (1), 99-115, 2019.
Pape, S., Gevers, T., Belias, M., et al.: Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis.
Clin. Gastroenterol. Hepatol. 17 (10), 2068-2075, 2019.
2018
Dinya, T., Tornai, T., Vitális, Z., Tornai, I., Balogh, B., Tornai, D., et al.: Functional polymorphisms of innate immunity receptors are not risk factors for the non-SBP type bacterial infections in cirrhosis.
Liver Int. 38 (7), 1242-1252, 2018.
Tornai, T., Tornai, D., Sipeki, N., Tornai, I., et al.: Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
Sci. Rep. 8 (1), 1-11, 2018.
Satishchandran, A., Ambade, A., Rao, S., Hsueh, Y., Iracheta-Vellve, A., Tornai, D., Lowe, P., Gyöngyösi, B., Li, J., Catalano, D., Zhong, L., Kodys, K., Xie, J., Bala, S., Gao, G., Szabó, G.: MicroRNA 122, Regulated by GRLH2, Protects Livers of Mice and Patients From Ethanol-Induced Liver Disease.
Gastroenterology. 154 (1), 238-252, 2018.
Pályu, E., Hársfalvi, J., Tornai, T., Papp, M., et al.: Major changes of von Willebrand factor multimer distribution in cirrhotic patients with stable disease or acute decompensation.
Thromb. Haemost. 118 (8), 1397-1408, 2018.
Sowa, M., Kolenda, R., Baumgart, D., Pratschke, J., Papp, M., Tornai, T., et al.: Mucosal autoimmunity to cell-bound GP2 isoforms is a sensitive marker in PSC and associated with the clinical phenotype.
Front. Immunol. 9 1-10, 2018.
Hunyady, B., Abonyi, M., Gerlei, Z., et al.: Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy.
Clin. Exp. Hepatol. 4 (2), 83-90, 2018.
2017
Tornai, T., Pályu, E., Vitális, Z., Tornai, I., Tornai, D., et al.: Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
World J. Gastroenterol. 23 (29), 5412-5421, 2017.
Földi, I., Tornai, T., Tornai, D., et al.: Lectin-complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections.
Liver Int. 37 (7), 1023-1031, 2017.
Fickert, P., Hirschfield, G., Denk, G., et al.: norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
J. Hepatol. 67 549-588, 2017.
2016
Dore, G., Conway, B., Luo, Y., et al.: Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials.
J. Hepatol. 64 (1), 19-28, 2016.
Tornai, T., Vitális, Z., Sipeki, N., Dinya, T., Tornai, D., et al.: Macrophage activation marker, soluble CD163 is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
Liver Int. 36 (11), 1628-1638, 2016.
Papp, M., Tornai, T., Vitális, Z., Tornai, I., Tornai, D., et al.: Presepsin teardown: pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis.
World J. Gastroenterol. 22 (41), 1-14, 2016.
2014
Pár, A., Pár, G., Tornai, I., et al.: IL28B and IL10R-1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
BMC Res Notes. 7 (1), 2014.
Sipeki, N., Antal-Szalmás, P., Lakatos, P., Papp, M.: Immune dysfunction in cirrhosis.
World J. Gastroenterol. 20 (10), 2564-2577, 2014.
Ferenci, P., Aires, R., Beavers, K., Curescu, M., et al.: Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients.
Hepatol Int. 8 (1), 83-93, 2014.
Lengyel, G., Gervain, J., Pár, G., Szalay, F., et al.: Real-World Virologic Response Rates and Prediction of Outcomes with Peginterferon Alfa-2a/Ribavirin in Hungarian HCV Genotype 1 Patients.
JGPLD. 1 (4), 1-8, 2014.
2013
Papp, M., Sipeki, N., Vitális, Z., Tornai, T., et al.: High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.
J. Hepatol. 59 (3), 457-466, 2013.
2012
Papp, M., Vitális, Z., Altorjay, I., Tornai, I., et al.: Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections.
Liver Int. 32 (4), 603-611, 2012.
2011
Pár, A., Kisfali, P., Melegh, B., Tornai, I., et al.: Cytokine (IL-10, IL-28B and LT-A) gene polymorphisms in chronic hepatitis C virus infection.
Clinical and Experimental Medical Journal. 5 (1), 9-19, 2011.
2010
Rejtő, L., Schlammadinger, Á., Ilonczai, P., Tornai, I., et al.: Treatment of mantle cell lymphoma with autologous stem-cell transplantation in a patient with severe congenital haemophilia-A and chronic (B and C virus) hepatitis.
Haemophilia. 16 706-709, 2010.
2005
Szalay, F., Folhoffer, A., Horváth, A., et al.: Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis.
Eur. J. Gastroenterol. Hepatol. 17 (9), 923-928, 2005.
2004
Lakatos, P., Bajnok, É., Tornai, I., et al.: Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis.
Eur. J. Gastroenterol. Hepatol. 16 (8), 753-759, 2004.
2003
Szalay, F., Hegedűs, D., Lakatos, P., Tornai, I., et al.: High serum osteoprotegerin and low RANKL in primary biliary cirrhosis.
J. Hepatol. 38 (4), 395-400, 2003.
